NasdaqGS - Delayed Quote USD

uniQure N.V. (QURE)

4.7500 -0.0700 (-1.45%)
At close: 4:00 PM EDT
4.7300 -0.02 (-0.42%)
After hours: 4:05 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Matthew Craig Kapusta CEO & Executive Director 1.16M -- 1972
Mr. Christian Klemt CFO, Principal Financial Officer & GM of Amsterdam Site 566.36k -- 1973
Mr. Pierre Caloz Chief Operating Officer 951.1k -- 1972
Prof. Hugo Katus Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany -- -- --
Mr. Richard Porter Ph.D. Chief Business & Scientific Officer -- -- --
Dr. Jeannette Potts J.D., Ph.D. Chief Legal & Compliance Officer -- -- 1962
Dr. Tamara Tugal Ph.D., MBA Business Development Director -- -- --
Ms. Carla Poulson Interim Chief People and Culture Officer -- -- --
Ms. Maria E. Cantor Chief Corporate Affairs Officer 491.12k -- 1968
Dr. Amin Abujoub Ph.D. Chief Quality Officer -- -- --

uniQure N.V.

Paasheuvelweg 25
Amsterdam, 1105 BP
Netherlands
31 20 240 6000 https://www.uniqure.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
480

Description

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Corporate Governance

uniQure N.V.’s ISS Governance QualityScore as of April 1, 2024 is 2. The pillar scores are Audit: 5; Board: 3; Shareholder Rights: 1; Compensation: 5.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 07, 2024 - May 13, 2024
uniQure N.V. Earnings Call

Related Tickers

RGNX REGENXBIO Inc.
15.90
+1.66%
 
GOSS Gossamer Bio, Inc.
0.7376
-0.73%
 
VYGR Voyager Therapeutics, Inc.
7.65
+1.06%
 
IMTX Immatics N.V.
10.42
+2.26%
 
FOLD Amicus Therapeutics, Inc.
10.71
-1.02%
 
ETNB 89bio, Inc.
8.92
-4.19%
 
KROS Keros Therapeutics, Inc.
55.19
-1.06%
 
STRO Sutro Biopharma, Inc.
3.7200
-1.33%
 
CLDX Celldex Therapeutics, Inc.
37.77
-2.78%
 
DAWN Day One Biopharmaceuticals, Inc.
16.64
+8.19%